48 active not recruiting. 48 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 48 | Active not recruiting 48 |
| Phase 2 | 3 | Active not recruiting 3 |
Follow Arthritis: new trials by email Literature Review of Arthritis trials Research Report on Arthritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tigulixostat (IBI128) vs Febuxostat in Gout Febuxostat, Tigulixostat - Gout | Phase 3 | Active not recruiting | Innovent Biologics Technology Limited (Shanghai R&D Center) | 600 | 2026-03-17 | 2026-09-01 |
| Single vs Triple Hyaluronic Acid in Knee Osteoarthritis Three intra-articular hyaluronic acid (HA) injections, One intra-articular hyaluronic acid (HA) injection - Osteoarthritis, Knee | Phase 2 / Phase 3 | Active not recruiting | University of Erlangen-Nürnberg Medical School | 46 | 2026-01-15 | 2026-05-14 |
| A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee Orforglipron, Placebo - Osteoarthritis | Phase 3 | Active not recruiting | Eli Lilly and Company | 800 | 2025-09-15 | 2026-10-08 |
| A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain. Pentosan Polysulfate Sodium twice weekly, Placebo - Osteoarthritis, Knee | Phase 3 | Active not recruiting | Paradigm Biopharmaceuticals Ltd. | 466 | 2025-05-29 | 2026-09-01 |
| A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis TLL-018 - Rheumatoid Arthritis | Phase 3 | Active not recruiting | Hangzhou Highlightll Pharmaceutical Co., Ltd | 350 | 2025-03-10 | 2026-09-25 |
| A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines Zasocitinib, Placebo - Psoriatic Arthritis | Phase 3 | Active not recruiting | Takeda | 601 | 2025-03-10 | 2026-10-14 |
| A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis Icotrokinra, Placebo, Active reference comparator - Arthritis, Psoriatic | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 552 | 2025-02-21 | 2026-11-03 |
| A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis Icotrokinra, Placebo - Arthritis, Psoriatic | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 813 | 2025-01-09 | 2026-11-03 |
| Nipocalimab in Moderate to Severe Sjogren's Disease Nipocalimab, Placebo, Standard of care treatment - Sjogrens Syndrome | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 655 | 2024-12-04 | 2026-11-03 |
| A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis SHR-1314 injection, Placebo - Psoriatic Arthritis | Phase 3 | Active not recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 208 | 2024-11-04 | 2026-08-06 |
| Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response Sonelokimab, Placebo, Risankizumab - Arthritis, Psoriatic | Phase 3 | Active not recruiting | MoonLake Immunotherapeutics AG | 600 | 2024-10-15 | 2026-10-09 |
| Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug Sonelokimab, Placebo - Arthritis, Psoriatic | Phase 3 | Active not recruiting | MoonLake Immunotherapeutics AG | 960 | 2024-10-15 | 2026-10-09 |
| A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis bimekizumab - Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis | Phase 3 | Active not recruiting | UCB Biopharma SRL | 89 | 2024-07-29 | 2026-07-17 |
| A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State Dazodalibep, Placebo - Sjögren's Syndrome (SS) | Phase 3 | Active not recruiting | Amgen | 434 | 2024-04-08 | 2026-01-08 |
| Microfragmented Adipose Tissue Compared to Saline Injection for the Treatment of Knee Osteoarthritis Microfragmented Adipose Tissue derived using the Lipogems® System, Saline Injection - Knee Osteoarthritis, Osteo Arthritis Knee | Phase 3 | Active not recruiting | Lipogems International spa | 173 | 2024-03-15 | 2025-06-12 |
| Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (LEVENTA) anti-TRBV9 monoclonal antibody infusions, Placebo infusions, Adalimumab subcutaneous injection - Axial Spondyloarthritis | Phase 3 | Active not recruiting | Biocad | 421 | 2023-12-25 | 2024-06-03 |
| A Study of LNK01001 Capsule in Subjects With Active Rheumatoid Arthritis (COURAGE-RA) LNK01001, Placebo - Rheumatoid Arthritis | Phase 3 | Active not recruiting | Lynk Pharmaceuticals Co., Ltd | 430 | 2023-12-12 | 2026-01-14 |
| A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome. Ianalumab (VAY736), Placebo - Sjogrens Syndrome | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 612 | 2023-10-27 | 2026-10-15 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis BMS-986278, BMS-986278 Placebo - Progressive Pulmonary Fibrosis | Phase 3 | Active not recruiting | Bristol-Myers Squibb | 1057 | 2023-10-25 | 2026-04-23 |
| A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome Deucravacitinib, Placebo - Sjögren's Syndrome | Phase 3 | Active not recruiting | Bristol-Myers Squibb | 774 | 2023-09-11 | 2026-04-01 |
Showing 20 of 48. Sign in to see all of them.
Arthritis, Psoriatic (15) · Osteoarthritis, Knee (12) · Arthritis, Rheumatoid (8) · Osteoarthritis (6) · Sjogren's Syndrome (5) · Joint Diseases (4) · Arthritis, Juvenile (3) · Musculoskeletal Diseases (3) · Axial Spondyloarthritis (2) · Colitis, Ulcerative (1) · Connective Tissue Diseases (1) · Crohn Disease (1) · Fever (1) · Fibrosis (1)
Musculoskeletal Diseases (45) · Joint Diseases (44) · Skin and Connective Tissue Diseases (32) · Rheumatic Diseases (30) · Bone Diseases (17) · Spinal Diseases (17) · Spondylarthritis (17) · Spondylarthropathies (17) · Spondylitis (17) · Autoimmune Diseases (16) · Connective Tissue Diseases (16) · Immune System Diseases (16) · Skin Diseases (16) · Psoriasis (15)
Adalimumab (3) · Sodium Chloride (3) · deucravacitinib (3) · risankizumab (3) · Injections (2) · ianalumab (2) · sonelokimab (2) · Abatacept (1) · Dronabinol (1) · Drug Implants (1) · Febuxostat (1) · GLPG0634 (1) · Hyaluronic Acid (1) · Interleukin 1 Receptor Antagonist Protein (1) · Methotrexate (1)
Bristol-Myers Squibb (5) · Janssen Research & Development, LLC (5) · AbbVie (3) · Eli Lilly and Company (3) · Biocad (2) · MoonLake Immunotherapeutics AG (2) · Novartis Pharmaceuticals (2) · Alfasigma S.p.A. (1) · Amgen (1) · Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León (1) · GID BIO, Inc. (1) · Hangzhou Highlightll Pharmaceutical Co., Ltd (1) · Innovent Biologics Technology Limited (Shanghai R&D Center) (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Lipogems International spa (1)
United States (31) · Spain (25) · Germany (24) · Poland (23) · Italy (19) · United Kingdom (19) · Argentina (18) · Australia (18) · France (18) · Taiwan (18) · Canada (17) · China (17) · Czechia (17) · Hungary (17) · Japan (16)
Arina Zinkina-Orikhan, PhD, MD (1) · John Tesser, MD (1) · Joshua F. Baker, MD MSCE (1)
PMID 36178584, PMID 38739215, PMID 39120849, PMID 41028616, PMID 41318485, PMID 31362993, PMID 31610021, PMID 33115760, PMID 33148701, PMID 33590829, PMID 34041702, PMID 34586459, PMID 34815219, PMID 34897366, PMID 34911706, PMID 35701011, PMID 35801915, PMID 36018230, PMID 36125701, PMID 36282530, PMID 36282537, PMID 36627711, PMID 36715850, PMID 36754548, PMID 36794283, PMID 37308218, PMID 37945286, PMID 37982966, PMID 38475923, PMID 38498139, PMID 38498140, PMID 38498141, PMID 38806190, PMID 39412672, PMID 40514717, PMID 40803820, PMID 40875187, PMID 41039829, PMID 41429981, PMID 41785908, PMID 42184973, PMID 42342288
2023 (9), 2017 (2), 2018 (1), 2019 (1), 2025 (1)